Insys founder John Kapoor is using the coronavirus pandemic as part of his legal defense to remain out of prison while he appeals his January 2020 racketeering conviction for kickback schemes to boost prescriptions of his company’s powerful opioid Subsys.
Value has so many meanings, but unfortunately the term has become synonymous with cost in the media/political landscape. As agency partners, we can help redefine how our clients communicate value to all audiences: HCPs, patients, caregivers, payers, investors, media at large and even to employees.
Twenty one states rejected an $18 billion settlement proposal from three major U.S. drug distributors to resolve lawsuits over their alleged role in the opioid crisis, although settlement discussions continue, according to two sources familiar with the matter.
John Kapoor, the founder and former chief executive officer of Insys Therapeutics, was sentenced to more than five years in federal prison for the role his company played in the opioid epidemic.
John Kapoor, the founder of Insys Therapeutics Inc., could be sentenced to several years in prison and ordered to forfeit up to $113 million for his role in a bribery and fraud scheme that contributed to the U.S. opioid crisis.
The U.S. Senate confirmed Stephen Hahn as commissioner of the U.S. Food and Drug Administration in a 72-18 vote.
The U.S. Supreme Court turned away a novel case by Arizona seeking to recover billions of dollars that the state has said that members of the Sackler family – owners of Purdue Pharma LP – funneled out of the OxyContin maker before the company filed for bankruptcy in September 2019.
Federal prosecutors are investigating six pharmaceutical companies for potential criminal charges in connection with shipping large quantities of opioid painkillers that contributed to a healthcare crisis, according to regulatory filings.
The U.S. Food and Drug Administration declined to approve Adamis Pharmaceuticals Corp.’s opioid overdose treatment Zimhi, sending the company’s shares plunging 56 percent.
Purdue Pharma LP will ask a U.S. Bankruptcy Judge to pause litigation against the company and ownership over the objections of U.S. states that allege the OxyContin maker is trying to protect the controlling Sackler family.